San Francisco startup Composition Therapeutics is additionally focusing on an oral, when-daily GLP-1 drug known as GSBR-1290—the drug surpassed Wall Avenue’s expectations in June any time a mid-phase study showed regular weight loss of all-around 6% and it options to start out A diff